Core Points - The company has successfully included several of its products in the National Medical Insurance Catalog for 2025, which is expected to enhance sales and improve operational performance [1] - The total estimated sales for the included drugs in 2024 is approximately 8.66 billion yuan, and for the first three quarters of 2025, it is about 7.55 billion yuan [1] Drug Inclusion in National Medical Insurance Catalog - The following drugs have been newly included: - Injection of Rukang Qutuzumab - Apixaban Famitinib Capsules - Injection of Funaqi Zhumab - Sulfate of Amatuximab Tablets - Injection of Phosphorola Pitant Palonosetron - Injection of Ruikasi Zhumab - Acetate of Abiraterone Tablets (II) - Lipid Injection of Irinotecan Hydrochloride (II) - Regaglitin Metformin Tablets (I)/(II) - Perfluorohexyl Octane Eye Drops [1] - The following drugs have successfully added new indications: - Injection of Karelizumab - Fluorazepam Capsules - Injection of Fumaric Acid Tegafur [1] - The following drugs have been renewed and retained in the National Medical Insurance Catalog: - Maleate of Pyrotinib Tablets - Hecorapam Ethanolamine Tablets - Phosphate of Regaglitin Tablets - Injection of Methylsulfonylmethane Remazolam - Sulfate of Pevonedistat Injection [1] - The following drugs have new indications and have been adjusted to regular catalog management: - Mesylate of Apatinib Tablets - Lipid Injection of Bupivacaine [1] Impact on the Company - The inclusion of these drugs in the National Medical Insurance Catalog is expected to positively impact sales, although the exact effect on the company's operational performance is currently indeterminate [1] - The National Medical Insurance Catalog will officially take effect on January 1, 2026, with further details on payment standards and reimbursement rules to be announced by relevant government departments [1]

证券代码：600276 证券简称：恒瑞医药 公告编号：临2025-194 江苏恒瑞医药股份有限公司关于公司药品纳入国家医保目录的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 根据国家医保局、人力资源社会保障部关于印发《国家基本医疗保险、工伤保险和生育保险药品目录 （2025年）》的通知（"《国家基本医疗保险、工伤保险和生育保险药品目录》"以下简称"国家医保目 录"），江苏恒瑞医药股份有限公司（以下简称"恒瑞医药"或"公司"）部分产品纳入国家医保目录。 通过医保谈判，注射用瑞康曲妥珠单抗、苹果酸法米替尼胶囊、夫那奇珠单抗注射液、硫酸艾玛昔替尼 片、注射用磷罗拉匹坦帕洛诺司琼、注射用瑞卡西单抗、醋酸阿比特龙片（Ⅱ）、盐酸伊立替康脂质体 注射液（Ⅱ）、瑞格列汀二甲双胍片（Ⅰ）/（Ⅱ）、全氟己基辛烷滴眼液首次纳入国家医保目录；注 射用卡瑞利珠单抗、氟唑帕利胶囊、富马酸泰吉利定注射液新增适应症成功纳入国家医保目录；马来酸 吡咯替尼片、海曲泊帕乙醇胺片、磷酸瑞格列汀片、注射用甲苯磺酸瑞马唑仑、硫培非格司亭注射液续 约成功保留在国家 ...

公司上述药品2024年度合计销售额约为86.60亿元，2025年1-3季度合计销售额约为75.54亿元。公司上述 药品纳入国家医保目录，将有利于药品的销售，对公司经营业绩的影响暂无法估计。国家医保目录 (2025年)将于2026年1月1日起正式实施，医保支付标准、医保报销细则等相关信息，需以国家医疗保障 局等相关政府部门公示信息为准。敬请广大投资者谨慎投资，注意防范投资风险。 格隆汇12月7日丨恒瑞医药(600276.SH)公告，根据国家医保局、人力资源社会保障部关于印发《国家基 本医疗保险、工伤保险和生育保险药品目录(2025年)》的通知("《国家基本医疗保险、工伤保险和生育 保险药品目录》"以下简称"国家医保目录")，江苏恒瑞医药股份有限公司(以下简称"恒瑞医药"或"公 司")部分产品纳入国家医保目录。 通过医保谈判，注射用瑞康曲妥珠单抗、苹果酸法米替尼胶囊、夫那奇珠单抗注射液、硫酸艾玛昔替尼 片、注射用磷罗拉匹坦帕洛诺司琼、注射用瑞卡西单抗、醋酸阿比特龙片(Ⅱ)、盐酸伊立替康脂质体注 射液(Ⅱ)、瑞格列汀二甲双胍片(Ⅰ)/(Ⅱ)、全氟己基辛烷滴眼液首次纳入国家医保目录；注射用卡瑞利 珠单抗、氟唑帕利胶囊 ...

【#恒瑞医药10款新药首次进入医保目录#】#2025医保药品目录公布# 记者从今日举行的2025创新药高 质量发展大会现场获悉，恒瑞医药共10款产品首次被纳入新版国家医保药品目录，覆盖肿瘤、代谢、心 血管疾病、免疫系统疾病、眼科等多个领域，具体包括注射用瑞康曲妥珠单抗、硫酸艾玛昔替尼片、夫 那奇珠单抗注射液、注射用瑞卡西单抗、注射用磷罗拉匹坦帕洛诺司琼、瑞格列汀二甲双胍片(I)/(II)、 苹果酸法米替尼胶囊、醋酸阿比特龙片（II）、盐酸伊立替康脂质体注射液（II）、全氟己基辛烷滴眼 液。（智通财经） ...

Core Viewpoint - Heng Rui Medicine (01276.HK) has received approval from the National Medical Products Administration for clinical trials of Sulfate Emamectin Benzoate Tablets and SHR0302 Gel, aimed at treating vitiligo [1] Group 1: Company Developments - The company and its subsidiary, Ruishi Biopharmaceutical Co., Ltd., have been granted the Clinical Trial Approval Notice for the mentioned drugs [1] - The clinical trial applications for Sulfate Emamectin Benzoate Tablets and SHR0302 Gel were accepted on August 29, 2025, and have met the requirements for drug registration [1] Group 2: Product Information - The intended use for Sulfate Emamectin Benzoate Tablets is as a monotherapy or in combination with SHR0302 Gel for the treatment of vitiligo [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of Sulfate Emamectin Benzoate Tablets and SHR0302 Gel, indicating progress in its drug development pipeline [1] Group 1: Drug Approvals and Clinical Trials - The company and its subsidiary, Ruishi Biopharmaceutical Co., Ltd., have been granted a clinical trial approval notice for Sulfate Emamectin Benzoate Tablets and SHR0302 Gel [1] - Sulfate Emamectin Benzoate Tablets have already been approved for four indications in China, including treatment for adult patients with active ankylosing spondylitis and moderate to severe rheumatoid arthritis who have had inadequate response to TNF inhibitors [1] Group 2: Drug Mechanism and Market Context - Sulfate Emamectin Benzoate is a highly selective JAK1 inhibitor that exerts anti-inflammatory and immunosuppressive effects by inhibiting JAK1 signaling [1] - Currently, there are no oral drugs of the same class approved globally for the treatment of vitiligo, although a topical drug, Ruxolitinib cream (OPZELURA®), has been approved, with no sales data available [1] Group 3: Research and Development Investment - The cumulative R&D investment for Sulfate Emamectin Benzoate projects has reached approximately 1.091 billion yuan [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of Sulfate Emamectin and SHR0302 gel, indicating a significant advancement in its product pipeline [1] Group 1: Clinical Trial Approvals - The company and its subsidiary, Ruishi Biopharmaceutical Co., Ltd., have been granted the Clinical Trial Approval Notice for Sulfate Emamectin Tablets and SHR0302 gel [1] - Sulfate Emamectin Tablets have already been approved for four indications in China, including active ankylosing spondylitis and moderate to severe active rheumatoid arthritis [1] Group 2: Product Details - Sulfate Emamectin is a highly selective JAK1 inhibitor that exerts anti-inflammatory and immunosuppressive effects by inhibiting JAK1 signaling [1] - Currently, there are no oral counterparts approved globally for the treatment of vitiligo, although a topical drug, Ruxolitinib cream (OPZELURA), has been approved [1] Group 3: Research and Development Investment - The cumulative R&D investment related to Sulfate Emamectin has reached approximately 1.091 billion yuan [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of Sulfate Emamectin Benzoate Tablets and SHR0302 Gel, indicating progress in its drug development pipeline [1] Group 1: Company Developments - Heng Rui Medicine and its subsidiary, Ruishi Bio, have been granted the Clinical Trial Approval Notice for Sulfate Emamectin Benzoate Tablets and SHR0302 Gel [1] - Sulfate Emamectin Benzoate Tablets have already been approved for four indications in China, showcasing the company's existing market presence [1] - Sulfate Emamectin Benzoate is identified as a highly selective JAK1 inhibitor, which may position the company favorably in the competitive pharmaceutical landscape [1] Group 2: Regulatory Environment - The approval for clinical trials is a prerequisite for conducting further clinical studies and obtaining production and marketing approval from the National Medical Products Administration [1] - The company must adhere to the relevant laws and regulations regarding drug registration in China, which emphasizes the importance of regulatory compliance in the pharmaceutical industry [1]

Core Viewpoint - Heng Rui Medicine (600276) has received approval from the National Medical Products Administration for multiple clinical trial applications, indicating a significant advancement in its drug development pipeline [1] Group 1: Clinical Trial Approvals - The company and its subsidiary, Ruishi Biopharmaceutical Co., Ltd., have received approval for clinical trials of Sulfate Emamectin Benzoate Tablets and SHR0302 Gel, which will commence shortly [1] - Additionally, the company and its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd., Shanghai Heng Rui Medicine Co., Ltd., and Shanghai Shengdi Medicine Co., Ltd., have been granted approval for clinical trials of several products, including HRS-7058 Capsules, HRS-7058 Tablets, SHR-9839(sc), Adebali Injection, Bevacizumab Injection, and SHR-A2102 Injection, with trials set to begin soon [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of Sulfate Emamectin Benzoate Tablets and SHR0302 Gel, aimed at treating vitiligo [1] Group 1 - The company and its subsidiary, Ruishi Biopharmaceutical Co., Ltd., will soon initiate clinical trials for the approved drugs [1] - The indications for the drugs include the use of Sulfate Emamectin Benzoate Tablets alone or in combination with SHR0302 Gel for the treatment of vitiligo [1]